Quick Answer
ENANTA PHARMACEUTICALS INC reported Operating Income Loss of -$85.35 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +29.9% in Operating Income Loss from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ENANTA PHARMACEUTICALS INC's Operating Income Loss has declined by 437.4%.
- Historical annual values: Fiscal year 2025: -$85.35 million | Fiscal year 2024: -$121.69 million | Fiscal year 2023: -$137.21 million | Fiscal year 2022: -$123.84 million | Fiscal year 2021: -$109.57 million | Fiscal year 2020: -$41.64 million | Fiscal year 2019: $36.74 million | Fiscal year 2018: $88.33 million | Fiscal year 2017: $24.61 million | Fiscal year 2016: $30.84 million | Fiscal year 2015: $124.15 million | Fiscal year 2014: $18.99 million | Fiscal year 2013: $9.03 million | Fiscal year 2012: $21.29 million | Fiscal year 2011: $25.30 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: